RxDoctor Payments Data

Hamsa Gabbara, MD

Internal Medicine · Wyandotte, MINPI 1083234777

Payments from drug & device makers

$3,185in general payments, 2019–2025

Across 166 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$471
  • Corcept Therapeutics$317
  • AbbVie$308
  • AstraZeneca$257
  • Lilly USA, LLC$224
  • Pfizer$178
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,185 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$12,924
Medicare patients
76
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$102,094
OzempicSemaglutide56$73,501
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$47,223
JardianceEmpagliflozin31$36,896
EliquisApixaban23$27,884
TrulicityDulaglutide15$20,574
FarxigaDapagliflozin Propanediol16$15,959
EntrestoSacubitril/Valsartan17$14,869
XareltoRivaroxaban15$10,542
MyrbetriqMirabegron13$7,226
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,460
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,230
Albuterol Sulfate HfaAlbuterol Sulfate88$3,089
Varenicline Tartrate15$3,032
PaxlovidNirmatrelvir/Ritonavir12$2,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$224$122,66895 claims
Novo NordiskOzempic$471$73,50156 claims
GSKTrelegy Ellipta$64$47,22367 claims
Boehringer IngelheimJardiance$13$36,89631 claims
PfizerEliquis, Paxlovid$178$30,57835 claims
AstraZenecaFarxiga$257$15,95916 claims
Astellas Pharma US IncMyrbetriq$84$7,22613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Wyandotte

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →